significantly cognitive decline people received placebo amyloid build brains sets results provide support amyloid hypothesis idea amyloid deposits brain cause alzheimer effect removing stops disease creeping right direction says samuel gandy neurobiologist mount sinai school medicine new york lot euphoria things negative long solanezumab failed previous trials drug firms pfizer johnson johnson discontinued development antibody drug bapinezumab 2012 trials 2,400 people failed roche halted 3,000 person trial anitbody candidate gantenerumab december presented results week showing highest dose drug entered brain reduced amyloid protein patients fast progressing disease experts greeting results biogen lilly news tempered excitement given relatively small size clinical